Vitamin K2 may shield Kids' bones from steroid side effects
NCT ID NCT07206537
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether vitamin K2 supplements can prevent bone loss in children with nephrotic syndrome who are on long-term steroid therapy. Steroids are effective but can weaken bones, increasing fracture risk. The trial will enroll 60 children under 16 and measure changes in bone strength and bone-related blood markers.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vitamin K2
- What this could lead to
- If it works, this could point toward a simple, safe way to protect bone health in children who need long-term steroids.
- What could go wrong
- This is a small, early-stage study (60 children) with no placebo group, so results may not be conclusive. Vitamin K2 may not prevent bone loss as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Apr 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 16 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Nephrotic patients under 16 years of age of both genders who were treated with GC for the first time. GC treatment was initiated at a dose of 2 mg/kg/day prednisolone with gradual dose reduction. * All patients have been on glucocorticoid therapy for more than 6 months. All patients have sufficient vitamin D level 30 ng/ml (75 nmol/L) or above. Exclusion Criteria: 1. Patients with impaired kidney functions. 2. Non-compliant patients on medications or vitamin supplements. 3. Diseases that affect fat-soluable vitamins absorption such as gallbladder or biliary disease, cystic fibrosis, celiac disease, etc. 4. History of vitamin K-related disorders as bleeding disorders, osteomalacia , etc. 5. History of bone fracture before the study. 6. Any nephrotic syndrome with identified genetic causes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pediatrics nephrology are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ain Shams University
RECRUITINGCairo, Egypt